Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...
1don MSN
Lifelong drugs for autoimmune diseases don’t work well. Now scientists are trying something new
There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...
Prognostic value of time-varying patient-reported symptoms and quality of life in cancer patients receiving chemotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...
Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
The global car t-cell therapy market size is predicted to increase from USD 7.64 billion in 2025 and is anticipated to be worth around USD 146.55 billion by 2034, expanding at a CAGR of 38.83% from ...
India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in ...
Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...
Patients relapsing within three months post-CAR T-cell therapy have lower response rates to BsAb therapy compared to those relapsing after six months. Elevated LDH levels and higher international ...
AP Newsroom on MSN
How CAR-T therapy works in autoimmune diseases
CAR-T therapy was originally developed for leukemias and lymphomas, and the breakthrough treatment is now also being used for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback